Calendar

Lennar had a valid after-close date and some operational positives, including sequentially improved gross margin, lower cycle time, and a solid balance sheet, but consensus still expected EPS of $1.31 and revenue of $8.396 billion against a weak housing backdrop; the recent rebound was not enough to offset the absence of positive estimate revisions and the lack of clean accumulation.

Rejected because FedEx company IR shows fiscal fourth-quarter results were reported on June 23, 2026 and the next earnings call was scheduled for October 28, so the supplied September 16 event is not a valid pre-earnings event.

Rejected because AAR reported fiscal fourth-quarter 2026 results on July 21, 2026 and its investor-events page showed no upcoming earnings event corresponding to September 21.

AutoZone had a strong prior quarter, positive same-store sales, and a small three-month revenue-estimate improvement, but the current whisper was below consensus, EPS revisions were flat to slightly negative, the stock was down over five and twenty sessions, and the highest recent volume did not clear the 1.5x threshold on a clean accumulation day.

Thor Industries had a confirmed before-open date and some diversification support from European and supplier businesses, but EPS and revenue estimates were revised lower, management cut full-year EPS guidance, prior-quarter sales and gross margin declined, and the stock was weak into the print without verified accumulation.

KB Home had a confirmed date and a possible built-to-order operating improvement, but both EPS and revenue estimates were revised lower, prior-quarter deliveries, revenue, income, backlog, and average selling price were weak, and the stock remained sharply below late-August levels; the isolated high-volume rebound was not enough to establish an upside-surprise setup.

Rejected because Ferguson reported fiscal second-quarter 2026 results on August 10, 2026 and company materials indicated the next results were expected November 9, not September 22.

News tone is mixed: strong H1 growth and U.S. manufacturing progress were outweighed by the Q2 consensus miss, non-reaffirmed guidance and a sharp initial share-price decline. The packet provides no sufficient social, options, short-interest or employee-sentiment data; analyst revision and target-change evidence is also unavailable. The later price recovery to approximately $4.82 does not yet establish a durable thesis reversal.

This is a cautious post-earnings monitoring setup. The primary company update supports runway and planned clinical milestones, but the earnings surprise was a small miss and the reported immediate price reaction was modestly negative ([MarketBeat](https://www.marketbeat.com/earnings/reports/2026-8-11-sagimet-biosciences-inc-series-a-stock/), [TipRanks](https://www.tipranks.com/stocks/sgmt)). The packet contains no recent-news or social-coverage signal, so missing analyst and market-depth evidence should not be interpreted as positive sentiment.

Primary company and SEC materials are directionally constructive on clinical execution, but forward visibility remains limited. The stock moved from $3.97 on August 11 to $4.17 on August 19, then $4.12 on August 20 and $4.15 on August 21; this was a modest net rise followed by a pullback, without reliable attribution to earnings or guidance. The scheduled packet labels the earnings date as August 19, while the company and SEC earnings release is dated August 11, creating timing ambiguity. No dependable analyst revision or social-sentiment signal is available. The setup remains low-coverage, event-driven monitoring rather than a high-conviction bullish thesis.

The company has now confirmed the Q2 release and Q3 outlook through its investor-relations press release. Secondary market data shows a modest post-print decline followed by a rebound into the August 21 anchor close; estimate revisions appear mixed-to-positive, but coverage remains thin and no clean post-earnings target-change series is available. Social, options, short-interest, and employee-sentiment data are unavailable, so conviction remains limited. [#IR-2026-08-19] [TipRanks](https://www.tipranks.com/stocks/ymm/earnings)

The company source is concrete: Immunome’s August 11 SEC 8-K Exhibit 99.1 reported Q2 results, RINGSIDE outcomes, FDA acceptance of the varegacestat NDA, pipeline progress, and runway into 2028. Price action was initially positive but volatile, with gains on August 11-12 followed by a decline on August 13; the latest RankAlpha anchor was $28.52 on August 21. Secondary analyst data show Wedbush and Truist raised targets on August 12 while maintaining positive ratings, but no verified consensus EPS surprise or broader estimate-revision series is available. The deterministic prior remains negative, so this is a milestone-driven monitoring setup rather than a high-conviction long. [#SEC-8K-2026-08-11] https://stockanalysis.com/stocks/imnm/history/

Post-print tone is positive but increasingly valuation-sensitive. Target initially rose about 4% after the beat-and-raise report and reached a fresh 52-week high, while shares briefly traded lower the following day before recovering. Multiple analysts raised targets, but reported average targets remain near the current price. Social coverage was not sufficient for a reliable score, so conviction rests primarily on the company filing and earnings release rather than social momentum.